Drug intelligence / Profile preview

fluoxetine + choline

Development stage
Approved
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination of fluoxetine**, a selective serotonin reuptake inhibitor (SSRI), and **choline**, an essential nutrient and precursor of the neurotransmitter acetylcholine. There is no evidence of an FDA-approved or branded pharmaceutical product containing both fluoxetine and choline as a fixed combination, but research studies in animal models have investigated their synergistic effects on memory and neurobehavioral function under chronic mild stress. Fluoxetine increases synaptic serotonin by inhibiting its reuptake, commonly used to treat depression, OCD, and other psychiatric disorders[3][8]. Choline is a dietary nutrient necessary for the synthesis of acetylcholine, which plays roles in memory and cognitive function. Combined administration has been shown in rat models to improve memory retention and produce earlier cognitive effects compared to choline alone, suggesting possible synergy between serotonergic and cholinergic neurotransmitter systems[5]. No combination product with this formula is currently known to be marketed.

Brand names
GaboxetineSentraflox AM-10Sentroxatine
02

Targets

SERT (Sodium-dependent serotonin transporter)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on fluoxetine + choline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + choline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call